# Dr Agarwals Eye Hospital share price today (Dr Agarwals Eye Hospital Ltd, NSE: DRAGARWQ)

> Dr Agarwals Eye Hospital share price today: ₹5,423.00 at the NSE close on 4 November 2026, up 4.0% in a year. Dr Agarwals Eye Hospital (NSE: DRAGARWQ) is worth ₹2,621 crore, trades at a P/E of 34.4 and has closed between ₹4,474.55 and ₹5,735.30 over the past 52 weeks. > Dr Agarwals Eye Hospital Ltd's earnings have grown faster than its share price. Earnings per share grew +24.7% in a year while the price moved +4.0%. DRAGARWQ · Hospitals · data as of 4 November 2026. Page: https://www.sectoralpha.in/stocks/dr-agarwals-eye-hospital-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Growing steadily, from the last 12 quarters
- Price: ₹5,423.00 (+4.0% in a year)
- P/E: 34.4× (higher than 68% of the last 11 years)
- Revenue (Jun 2026): ₹143 Cr (+22.2% on a year ago)
- Profit (Jun 2026): ₹23.0 Cr (+35.3% on a year ago)
- Operating margin: 30.0% (−2.0 points on a year ago)
- ROCE: 17%, FY26
- ROIC: 13.7%, against a 12.0% cost of capital: +1.7 points

Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. ## What is the Dr Agarwals Eye Hospital share price today? Dr Agarwals Eye Hospital Ltd's share price was ₹5,423.00 at the close on 4 November 2026. It has been rising for 24 weeks. That is 7.1% above its average price over the last 200 trading days. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 14 weeks in a row. In the last 52 weeks it traded between ₹4,475 and ₹5,735, and at that close it sat 75% of the way up from that low. Over the last 11 years the share price moved +2,800% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Dr Agarwals Eye Hospital this quarter? Three changes stood out: revenue up on a year earlier for 11 quarters in a row (every quarter we can compare), highest quarterly profit in 15 quarters and highest quarterly revenue in 15 quarters. 1. Revenue up on a year earlier for 11 quarters in a row (every quarter we can compare) In the June 2026 quarter revenue was ₹143 crore, +22.2% on a year earlier. 2. Highest quarterly profit in 15 quarters Profit of ₹23 crore in the June 2026 quarter is the highest of the last 15 quarters. 3. Highest quarterly revenue in 15 quarters Revenue of ₹143 crore in the June 2026 quarter is the highest of the last 15 quarters. ## What are Dr Agarwals Eye Hospital's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Dr Agarwals Eye Hospital reported revenue of ₹143 crore, up 22.2% from ₹117 crore a year earlier, and a profit of ₹23.0 crore, up 35.3% from ₹17.0 crore. ### Dr Agarwals Eye Hospital results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹143 crore | ₹117 crore | +22.2% |
| Profit | ₹23.0 crore | ₹17.0 crore | +35.3% |
| Earnings per share | ₹48.38 | ₹36.72 | +31.8% |
| Operating margin | 30.0% | 32.0% | −2.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Dr Agarwals Eye Hospital share price history? Dr Agarwals Eye Hospital closed at ₹5,423.00 on 4 November 2026, up 4.0% from ₹5,213.15 a year earlier (7 November 2025) and up 834.6% over five years. Its highest weekly close since March 2016 was ₹6,936.15 on 17 January 2025. ### Dr Agarwals Eye Hospital share price: then and now

| When | Close | Change to 4 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 30 Oct 2026 | ₹5,280.15 | +2.7% |
| 1 month ago · 1 Oct 2026 | ₹5,181.20 | +4.7% |
| 6 months ago · 8 May 2026 | ₹5,101.30 | +6.3% |
| 1 year ago · 7 Nov 2025 | ₹5,213.15 | +4.0% |
| 3 years ago · 3 Nov 2023 | ₹2,773.65 | +95.5% |
| 5 years ago · 4 Nov 2021 | ₹580.25 | +834.6% |
| 10 years ago · 4 Nov 2016 | ₹283.20 | +1,814.9% |
| Earliest weekly close in our records · 10 Mar 2016 | ₹187.00 | +2,800.0% |
| Highest weekly close since March 2016 · 17 Jan 2025 | ₹6,936.15 | −21.8% |
| Lowest weekly close since March 2016 · 11 May 2016 | ₹155.00 | +3,398.7% |
| 52-week high (weekly close) · 28 Nov 2025 | ₹5,735.30 | −5.4% |
| 52-week low (weekly close) · 6 Mar 2026 | ₹4,474.55 | +21.2% |

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (558 weekly closes from 10 March 2016 to 4 November 2026.)

## What is the latest news on Dr Agarwals Eye Hospital? 4 Nov 2026: Dr Agarwals Eye Hospital closed at ₹5,423.00, up 2.7% on the week and up 4.7% on the month. 2 Sep 2026: ex-date for a dividend of ₹4 a share. ### Earlier

- Results for April to June 2026: Revenue up 22.2% and profit up 35.3% on a year earlier. ## What dividend does Dr Agarwals Eye Hospital pay? Dr Agarwals Eye Hospital paid ₹4 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.07% at the ₹5,423.00 close on 4 November 2026. The last was a dividend of ₹4 a share, ex-date 2 September 2026. ### Dr Agarwals Eye Hospital dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 2 Sep 2026 | ₹4 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 0 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Dr Agarwals Eye Hospital Ltd paid out 5% of its profit as dividends in FY26, and it paid a dividend in 11 of its last 13 reported years. (From the NSE corporate-actions record, read 5 November 2026.)

## Which stock lists is Dr Agarwals Eye Hospital on? Dr Agarwals Eye Hospital is on one of our India lists: Momentum stocks. [Momentum stocks Market cap cr: 2620.989186647861](https://www.sectoralpha.in/momentum-stocks-india)

## Is Dr Agarwals Eye Hospital profitable? Dr Agarwals Eye Hospital Ltd earned ₹23.0 Cr of net profit in the Jun 2026 quarter, +35.3% on the same quarter a year earlier. Full-year FY26 profit was ₹70.0 Cr. That is 16.1% of the quarter's revenue. The same quarter a year earlier earned ₹17.0 Cr. For the full year, FY26 profit was ₹70.0 Cr (+27.3% on the year before). Why profit moved: revenue changed +22.2% on a year earlier and the margin moved −2.0 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed +35.3% and revenue +20.0%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Dr Agarwals Eye Hospital make, and is it growing? Dr Agarwals Eye Hospital Ltd reported ₹143 Cr of revenue in the Jun 2026 quarter, +22.2% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 13.1% a year on average. The last full year, FY26, came in at ₹471 Cr. The last four reported quarters add to ₹497 Cr. FY26 revenue was ₹471 Cr, +18.6% on the year before. Recent pace: the last four quarters grew +20.0% on average, against 13.1% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +20.0%, against +20.7% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +31.6%, against +23.7% a year (accelerating). ## How much of every ₹100 of sales does Dr Agarwals Eye Hospital keep? Dr Agarwals Eye Hospital Ltd's operating margin was 30.0% in the Jun 2026 quarter, 2.0 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between 9.0% and 31.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −1.5 percentage points on the year while gross margin changed +1.0 points. So the drop came mostly from the gross margin, which means input costs and prices charged. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is Dr Agarwals Eye Hospital's profit turning into cash? Over the last 3 years, 192% of Dr Agarwals Eye Hospital Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹145 Cr of operating cash against ₹70.0 Cr of profit. After ₹125 Cr of spending on assets, ₹20.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 192% of profit came in as cash: the cash cycle got 229 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 3.5× depreciation over three years. The next section checks what that spending is building. ## Where does Dr Agarwals Eye Hospital's cash go? Dr Agarwals Eye Hospital Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −31 days in FY26, up from −260 days in FY21. It spent ₹390 Cr on assets over the last 3 years. Customers take 14 days to pay, and stock sits for 51 days on average. At FY26 sales of ₹471 Cr, each day of that cycle ties up about ₹1.3 Cr, so roughly −₹40.0 Cr is tied up in the business at any time. FY26: customers took 14 days to pay and stock sat for 51 days, about 1.7 months of sales sitting as stock, for a full cycle of −31 days, longer than FY21's −260. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 51 days. Customers pay about 14 days after that. Suppliers are paid at 97 days. Together that makes the −31-day cycle. Spending on assets: ₹390 Cr over the last 3 years, against ₹112 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹197 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Dr Agarwals Eye Hospital's P/E ratio, and how does it compare with its own history? Dr Agarwals Eye Hospital Ltd's P/E is 34.4×, in the middle of its own history: higher than 68% of past readings. Its usual P/E (the middle reading) is 29.5×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +24.7% while the price moved +4.0%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +56.4% a year; about +37.1% a year came from earnings growth and about +19.3 percentage points from the multiple (the market paying more); over 10 years the price moved +34.3% a year; about +37.6% a year came from earnings growth and about −3.3 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Dr Agarwals Eye Hospital business getting better or worse? Dr Agarwals Eye Hospital Ltd's business is growing steadily. Revenue, profit and EPS growth have stayed positive throughout, and ROCE is steady at 19.0%. This is based on 12 quarters of 4 measures. Why it matters: steady growth with healthy returns is how a business compounds over time. ## How much does Dr Agarwals Eye Hospital earn on its capital? Dr Agarwals Eye Hospital Ltd earned a ROCE of 17% in FY26. That is up from a low of 11% in FY21. Its return on capital used (ROIC) is 1.7 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 14.9% net margin and 0.61× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 14.9% net margin × 0.61× asset turnover × 2.21× leverage (assets divided by equity) ≈ 20.1% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 13.7% − 12.0% = +1.7 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. ## Does Dr Agarwals Eye Hospital have too much debt? Dr Agarwals Eye Hospital Ltd has total debt of ₹326 Cr against shareholder equity of ₹346 Cr as of Jun 2026, so its debt is 0.94× its equity. Year by year, that ratio went from 2.47 in FY22 to 0.94 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Dr Agarwals Eye Hospital shareholding pattern? Domestic institutions raised their stake in Dr Agarwals Eye Hospital Ltd by 1.6 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 2.5% of the company. Foreign institutions moved +1.4 points over the same period, to 2.2%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Domestic institutions: +1.6 points over 8 quarters, to 2.5%; Foreign institutions: +1.4 points over 8 quarters, to 2.2%; Promoters: +0.8 points over 8 quarters, to 72.7%. Why the owners changed: domestic institutions drove it (+1.6 points), together with foreign institutions (+1.4 points). They raised their stake step by step. ## How far is Dr Agarwals Eye Hospital from balance-sheet trouble? For Dr Agarwals Eye Hospital Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Dr Agarwals Eye Hospital rank in its industry? 62.5 out of 100, rank 4 of 20 in Hospitals, with 81% of the evidence available. Dr Agarwals Eye Hospital Ltd scores 62.5 out of 100 against the 20 companies it is compared with in Hospitals, ranking 4. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 21.1 + 17.3 + 12.5 + 11.6 = 62.5. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Dr Agarwals Eye Hospital compared with? Dr Agarwals Eye Hospital ranks 4 of 20 Hospitals companies on the 4-Factor Sector Score, with 62.5 out of 100. 1. [KMC Speciality Hospitals (India) Ltd](https://www.sectoralpha.in/stocks/kmc-speciality-hospitals-indialtd) KMCSHIL · breaking out · Sector-leading setup · 81% evidence 80.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.0/35 · Revenue 35.1% · Profit 100% · Operating margin change 6 points · 88% evidence Capital efficiency 23.0/25 · ROCE 26.2% · Operating margin 31% · 100% evidence Valuation 14.1/20 · P/E 43.4× · PEG 0.68 · 100% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 45.6% · 1 year 115.4% · 25% evidence · 5 of 5 weeks ahead Exact sum: 31 + 23 + 14.1 + 12.5 = 80.6 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Sakar Healthcare Ltd](https://www.sectoralpha.in/stocks/sakar-healthcare-ltd) SAKAR · leader · Most evidence points up · 100% evidence 68.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.5/35 · Revenue 47.5% · Profit 100% · Operating margin change 8 points · 100% evidence Capital efficiency 11.4/25 · ROCE 12.4% · Operating margin 28% · 100% evidence Valuation 11.1/20 · P/E 49× · PEG 1.05 · 100% evidence Relative strength 13.8/20 · Lead over its industry 41.8% · Lead over NIFTY 500 45.4% · 1 year 161.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 32.5 + 11.4 + 11.1 + 13.8 = 68.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Apollo Hospitals Enterprise Ltd](https://www.sectoralpha.in/stocks/apollo-hospitals-enterprise-ltd) APOLLOHOSP · turning · Most evidence points up · 78% evidence 68.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 17.2% · Profit 33.2% · Operating margin change 1 points · 83% evidence Capital efficiency 15.2/25 · ROCE 17.4% · Operating margin 16% · 76% evidence Valuation 12.7/20 · P/E 57.7× · PEG n/a · 50% evidence Relative strength 16.6/20 · Lead over its industry 6.6% · Lead over NIFTY 500 11.2% · 1 year 10% · 100% evidence · 4 of 12 weeks ahead Exact sum: 24 + 15.2 + 12.7 + 16.6 = 68.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. Dr Agarwals Eye Hospital Ltd this page DRAGARWQ · breaking out · Evidence leans up · 81% evidence 62.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.1/35 · Revenue 20.1% · Profit 31.6% · Operating margin change -2 points · 88% evidence Capital efficiency 17.3/25 · ROCE 17.2% · Operating margin 30% · 100% evidence Valuation 12.5/20 · P/E 33.7× · PEG 1.36 · 100% evidence Relative strength 11.6/20 · Lead over its industry n/a · Lead over NIFTY 500 9.2% · 1 year 0.8% · 25% evidence · 8 of 12 weeks ahead Exact sum: 21.1 + 17.3 + 12.5 + 11.6 = 62.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Kovai Medical Center & Hospital Ltd](https://www.sectoralpha.in/stocks/kovai-medical-center-hospital-ltd) KOVAI · breaking out · Evidence leans up · 96% evidence 61.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.8/35 · Revenue 15% · Profit 15.8% · Operating margin change 1 points · 88% evidence Capital efficiency 19.1/25 · ROCE 22.6% · Operating margin 29% · 100% evidence Valuation 8.9/20 · P/E 24.8× · PEG 2.01 · 100% evidence Relative strength 14.7/20 · Lead over its industry 1.9% · Lead over NIFTY 500 6.6% · 1 year -9.2% · 100% evidence · 10 of 12 weeks ahead Exact sum: 18.8 + 19.1 + 8.9 + 14.7 = 61.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [GPT Healthcare Ltd](https://www.sectoralpha.in/stocks/gpt-healthcare-ltd) GPTHEALTH · quiet · Evidence leans up · 81% evidence 61.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.4/35 · Revenue 18% · Profit 0% · Operating margin change 3 points · 88% evidence Capital efficiency 18.1/25 · ROCE 19.9% · Operating margin 19% · 100% evidence Valuation 18.5/20 · P/E 23× · PEG 0.94 · 100% evidence Relative strength 9.1/20 · Lead over its industry n/a · Lead over NIFTY 500 -2.1% · 1 year -10.7% · 25% evidence · 4 of 12 weeks ahead Exact sum: 15.4 + 18.1 + 18.5 + 9.1 = 61.1 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 7. [Yatharth Hospital & Trauma Care Services Ltd](https://www.sectoralpha.in/stocks/yatharth-hospital-trauma-care-services-ltd) YATHARTH · breaking out · Evidence leans up · 78% evidence 57.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.4/35 · Revenue 43.9% · Profit 22.5% · Operating margin change -2 points · 83% evidence Capital efficiency 12.4/25 · ROCE 12.9% · Operating margin 23% · 76% evidence Valuation 6.7/20 · P/E 49.3× · PEG n/a · 50% evidence Relative strength 19.1/20 · Lead over its industry 17.1% · Lead over NIFTY 500 21.6% · 1 year 16.4% · 100% evidence · 10 of 12 weeks ahead Exact sum: 19.4 + 12.4 + 6.7 + 19.1 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Artemis Medicare Services Ltd](https://www.sectoralpha.in/stocks/artemis-medicare-services-ltd) ARTEMISMED · leader · Evidence leans up · 100% evidence 56.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.4/35 · Revenue 14.7% · Profit 20% · Operating margin change 0 points · 100% evidence Capital efficiency 12.7/25 · ROCE 14.6% · Operating margin 18% · 100% evidence Valuation 8.0/20 · P/E 39.7× · PEG 2.44 · 100% evidence Relative strength 16.7/20 · Lead over its industry 8.4% · Lead over NIFTY 500 12.9% · 1 year 18.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 19.4 + 12.7 + 8 + 16.7 = 56.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Global Health Ltd](https://www.sectoralpha.in/stocks/global-health-ltd) MEDANTA · losing its lead · Evidence leans up · 96% evidence 52.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.5/35 · Revenue 21.3% · Profit 3.4% · Operating margin change -2 points · 88% evidence Capital efficiency 18.8/25 · ROCE 17.4% · Operating margin 22% · 100% evidence Valuation 5.5/20 · P/E 59.7× · PEG 9.11 · 100% evidence Relative strength 14.2/20 · Lead over its industry 3.7% · Lead over NIFTY 500 8.1% · 1 year -3.1% · 100% evidence · 8 of 12 weeks ahead Exact sum: 13.5 + 18.8 + 5.5 + 14.2 = 52 · What this means: Relative strength against the index is 8.1%, and revenue and profit growth are weak. 10. [Indraprastha Medical Corporation Ltd](https://www.sectoralpha.in/stocks/indraprastha-medical-corporation-ltd) INDRAMEDCO · quiet · Evidence leans up · 85% evidence 51.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.3/35 · Revenue 10.8% · Profit 10.9% · Operating margin change 0 points · 100% evidence Capital efficiency 17.6/25 · ROCE 35.8% · Operating margin 19% · 100% evidence Valuation 13.2/20 · P/E 14.6× · PEG 1.47 · 100% evidence Relative strength 7.7/20 · Lead over its industry n/a · Lead over NIFTY 500 -19.7% · 1 year -49.6% · 25% evidence · 0 of 12 weeks ahead Exact sum: 13.3 + 17.6 + 13.2 + 7.7 = 51.8 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 11. [Rainbow Childrens Medicare Ltd](https://www.sectoralpha.in/stocks/rainbow-childrens-medicare-ltd) RAINBOW · quiet · Evidence leans up · 100% evidence 50.1 out of 100 Growth Capital Valuation Relative
12. [Max Healthcare Institute Ltd](https://www.sectoralpha.in/stocks/max-healthcare-institute-ltd) MAXHEALTH · quiet · Evidence leans down · 85% evidence 48.5 out of 100 Growth Capital Valuation Relative
13. [Fortis Healthcare Ltd](https://www.sectoralpha.in/stocks/fortis-healthcare-ltd) FORTIS · basing · Evidence leans down · 78% evidence 45.1 out of 100 Growth Capital Valuation Relative
14. [Shalby Ltd](https://www.sectoralpha.in/stocks/shalby-ltd) SHALBY · quiet · Evidence leans down · 63% evidence 42.0 out of 100 Growth Capital Valuation Relative
15. [Narayana Hrudayalaya Ltd](https://www.sectoralpha.in/stocks/narayana-hrudayalaya-ltd) NH · quiet · Evidence leans down · 78% evidence 40.7 out of 100 Growth Capital Valuation Relative
16. [Aster DM Quality Care Ltd](https://www.sectoralpha.in/stocks/aster-dm-quality-care-ltd) ASTERDM · quiet · Evidence leans down · 96% evidence 35.0 out of 100 Growth Capital Valuation Relative
17. [Krishna Institute of Medical Sciences Ltd](https://www.sectoralpha.in/stocks/krishna-institute-of-medical-sciences-ltd) KIMS · quiet · Most evidence points down · 78% evidence 34.8 out of 100 Growth Capital Valuation Relative
18. [Jupiter Life Line Hospitals Ltd](https://www.sectoralpha.in/stocks/jupiter-life-line-hospitals-ltd) JLHL · quiet · Most evidence points down · 100% evidence 33.0 out of 100 Growth Capital Valuation Relative
19. [Healthcare Global Enterprises Ltd](https://www.sectoralpha.in/stocks/healthcare-global-enterprises-ltd) HCG · quiet · Most evidence points down · 71% evidence 31.1 out of 100 Growth Capital Valuation Relative
20. [Manipal Health Enterprises Ltd](https://www.sectoralpha.in/stocks/manipal-health-enterprises-ltd) MANIPALHOS · Too little evidence to rank firmly · 38% evidence 42.4 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Hospitals](https://www.sectoralpha.in/sectors/hospitals), all 20 compared on one page. ## Which companies are close to Dr Agarwals Eye Hospital in size? Dr Agarwals Eye Hospital is the 16th largest of 20 Hospitals companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Kovai Medical Center & Hospital, Artemis Medicare Services and Indraprastha Medical Corporation. Just below it: KMC Speciality Hospitals (India), Sakar Healthcare and Shalby. ### Hospitals companies close in size

1. [Kovai Medical Center & Hospital Ltd](https://www.sectoralpha.in/stocks/kovai-medical-center-hospital-ltd) ₹6,363 crore
2. [Artemis Medicare Services Ltd](https://www.sectoralpha.in/stocks/artemis-medicare-services-ltd) ₹4,642 crore
3. [Indraprastha Medical Corporation Ltd](https://www.sectoralpha.in/stocks/indraprastha-medical-corporation-ltd) ₹2,802 crore
4. Dr Agarwals Eye Hospital Ltd ₹2,570 crore
5. [KMC Speciality Hospitals (India) Ltd](https://www.sectoralpha.in/stocks/kmc-speciality-hospitals-indialtd) ₹2,420 crore
6. [Sakar Healthcare Ltd](https://www.sectoralpha.in/stocks/sakar-healthcare-ltd) ₹2,102 crore
7. [Shalby Ltd](https://www.sectoralpha.in/stocks/shalby-ltd) ₹1,303 crore

[All 20 Hospitals companies, largest first](https://www.sectoralpha.in/sectors/hospitals#all-companies)

### Companies close in size in other industries

1. [ADF Foods Ltd](https://www.sectoralpha.in/stocks/adf-foods-ltd) ₹2,586 crore · FMCG - Contract Mfg
2. [Protean eGov Technologies Ltd](https://www.sectoralpha.in/stocks/protean-egov-technologies-ltd) ₹2,572 crore · IT Enabled Services
3. Dr Agarwals Eye Hospital Ltd ₹2,570 crore
4. [EFC (I) Ltd](https://www.sectoralpha.in/stocks/efc-iltd) ₹2,564 crore · Realty - CoWorking
5. [Marsons Ltd](https://www.sectoralpha.in/stocks/marsons-ltd) ₹2,558 crore · Capital Goods - Transformers

## What else do people ask about Dr Agarwals Eye Hospital? ### What is Dr Agarwals Eye Hospital's share price today? Dr Agarwals Eye Hospital Ltd's share price is ₹5,423.00, +4.0% over the past year. The whole company is worth ₹2,621 Cr on the market. In the last 52 weeks it traded between ₹4,475 to ₹5,735; today it is 75% of the way up from the low, 7.1% above its 200-day average (as of 4 November 2026). ### What were Dr Agarwals Eye Hospital's latest quarterly results? Dr Agarwals Eye Hospital Ltd reported revenue of ₹143 Cr and net profit of ₹23.0 Cr for the Jun 2026 quarter. Revenue rose 22.2% and profit rose 35.3% compared with a year earlier. Earnings per share were ₹48.38 (as of 4 November 2026). ### What is Dr Agarwals Eye Hospital's market cap? Dr Agarwals Eye Hospital Ltd's market capitalisation is ₹2,621 Cr at a share price of ₹5,423.00. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Dr Agarwals Eye Hospital performing? Dr Agarwals Eye Hospital Ltd's share price has been rising for 24 weeks. In its latest quarter, revenue rose 22.2% and profit rose 35.3% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 14 weeks running (as of 4 November 2026). ### Will Dr Agarwals Eye Hospital's share price go up? This page does not forecast Dr Agarwals Eye Hospital Ltd's share price. What it shows instead: the share price is ₹5,423.00, and it has been rising for 24 weeks. Its P/E of 34.4× is higher than 68% of its own last 11 years (as of 4 November 2026). ### Where is Dr Agarwals Eye Hospital in its business cycle? Dr Agarwals Eye Hospital Ltd's FY26 operating margin was 31.0%, against a 13-year range of 9.0% to 31.0%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 30.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Dr Agarwals Eye Hospital story? Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Dr Agarwals Eye Hospital a stock worth studying right now? What the numbers show: Dr Agarwals Eye Hospital Ltd's earnings have grown faster than its share price. Earnings per share grew +24.7% in a year while the price moved +4.0%. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). ## Lists

- Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india

This is research, not advice. We’re not SEBI-registered.